Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.46 EUR | -0.81% | -2.38% | +2.07% |
22/04 | BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment | MT |
11/04 | Gerresheimer shares down on outlook, but key contracts confirmed | RE |
Sales 2024 * | 77.05M 83.71M 6.99B | Sales 2025 * | 80.35M 87.3M 7.29B | Capitalization | 35.3M 38.35M 3.2B |
---|---|---|---|---|---|
Net income 2024 * | -1M -1.09M -90.71M | Net income 2025 * | - 0 0 | EV / Sales 2024 * | 0.59 x |
Net Debt 2024 * | 9.8M 10.65M 889M | Net Debt 2025 * | 6.7M 7.28M 608M | EV / Sales 2025 * | 0.52 x |
P/E ratio 2024 * |
-25.9
x | P/E ratio 2025 * |
-123
x | Employees | 1,071 |
Yield 2024 * |
2.44% | Yield 2025 * |
3.46% | Free-Float | 100% |
1 day | -0.81% | ||
1 week | -2.38% | ||
Current month | -1.60% | ||
1 month | -2.38% | ||
3 months | +2.07% | ||
6 months | -12.77% | ||
Current year | +2.07% |
Managers | Title | Age | Since |
---|---|---|---|
Kimmo Herranen
CEO | Chief Executive Officer | 51 | 01/05/01 |
Kalle Lehtonen
DFI | Director of Finance/CFO | 50 | 01/23/01 |
Director/Board Member | 54 | 01/94/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Risto Koivula
BRD | Director/Board Member | 56 | 16/21/16 |
Chairman | 58 | 01/18/01 | |
Director/Board Member | 56 | 01/22/01 |
Date | Price | Change | Volume |
---|---|---|---|
16/24/16 | 2.46 | -0.81% | 197 |
15/24/15 | 2.48 | +1.64% | 6,067 |
14/24/14 | 2.44 | -2.40% | 5,726 |
13/24/13 | 2.5 | -0.79% | 810 |
10/24/10 | 2.52 | -6.67% | 5,994 |
Delayed Quote Nasdaq Helsinki, May 16, 2024 at 04:50 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.07% | 38.68M | |
+9.59% | 7.42B | |
-12.31% | 291M | |
-.--% | 62.2M | |
-15.15% | 56.62M |
- Stock Market
- Equities
- ADMIN Stock